Article

The KRAS G12C mutation in NSCLC: from target to resistance

2021-05-20

Abstract excerpt

Lung cancer represents the most common form of cancer accounting for 1.8 million deaths globally in 2020.The 5-year relative survival rate for lung cancer is lower than many other leading cancer types. Over the last decade the treatment for advanced and metastatic non small cell lung cancer have dramatically improved due to the development of immune checkpoint inhibitors and the identification of targetable driver...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 73a88b98-c918-5bcc-87d0-44dcc150e395
DOI: 10.20944/preprints202105.0471.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The KRAS G12C mutation in NSCLC: from target to resistanceDOI 10.20944/preprints202105.0471.v1Read

Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential.Semantic proximity Read

Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).Semantic proximity Read

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future.Semantic proximity Read

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.Semantic proximity Read

On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.Semantic proximity Read

Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches.Semantic proximity Read

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.Semantic proximity Read

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Semantic proximity Read

Advances in the treatment of KRASG12C mutant non–small cell lung cancerSemantic proximity Read

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.Semantic proximity Read

Overcoming KRAS-Mutant Lung Cancer.Semantic proximity Read

KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies.Semantic proximity Read